20408-Breast Cancer-NA-1517

Breast Cancer

A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

  • Details

ClinicalTrials.gov ID: NCT04961996
Diagnosis Type: NA
USOR Number:

  • Address


,
P:

Search by practice name, trial titles, indicators and specific disease types.